Xianquan Zhan

Key Laboratory of Cancer Proteomics of Chinese Ministry of Health,

Xiangya Hospital,

Hunan Engineering Laboratory for Structural Biology and Drug Design,

State Local Joint Engineering Laboratory for Anticancer Drugs,

The State Key Laboratory of Medical Genetics,

National Clinical Research Center for Geriatric Disorders,

Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital,

Hunan Engineering Laboratory for Structural Biology and Drug Design, Xiangya Hospital,

State Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital,

National Clinical Research Center for Geriatric Disorders, Xiangya Hospital

Central South University

Xianquan Zhan received his M.D. and Ph.D. training in preventive medicine at West China University of Medical Sciences during 1989-1999. He received his post-doctoral training in oncology and cancer proteomics at Central South University and University of Tennessee Health Science Center (UTHSC). He worked at UTHSC and Cleveland Clinic in USA during 2001-2012, and achieved the rank of Associate Professor at UTHSC. In 2012, he moved to Central South University Xiangya Hospital as a Professor, and Advisors of MS/PhD graduate students and postdoctoral fellows. He is also the Fellow of Royal Society of Medicine, Fellow of EPMA, European EPMA National Representative, AAAS member, Editor-In-Chief of IJCDT, Execute Editor-in-Chief of Med One, Associate Editors of EPMA Journal and BMC Medical Genomics, and Guest Editors of Frontiers in Endocrinology (IF = 3.65) and Mass Spectrometry Reviews (IF = 9.068). He has published 130 articles, 16 book chapters, 3 books, and 2 US patents in the field of clinical proteomics and biomarkers. His research interests focus on the development and use of multi-omics (genomics, transcriptomics, proteomics, metabolomics, and radiomics) and systems biology to study cancer mechanisms, and discover effective biomarker pattern for predictive, preventive, and personalized medicine (PPPM) or precission medicine (PM) in cancer, and also focus on cancer proteoforms and post-translational modifications (PTMs).

Мы используем файлы cookie для улучшения качества работы на нашем веб-сайте.

Продолжая пользоваться нашим веб-сайтом или нажимая кнопку «Продолжить», вы соглашаетесь принять наши файлы cookie.

Подробнее